Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review

被引:45
作者
Poyatos, Lourdes [1 ,2 ,3 ,4 ]
Pilar Perez-Acevedo, Ana [1 ,2 ,3 ,4 ]
Papaseit, Esther [1 ,2 ,3 ,4 ]
Perez-Mana, Clara [1 ,2 ,3 ,4 ]
Martin, Soraya [1 ,2 ]
Hladun, Olga [1 ,2 ,3 ,4 ]
Siles, Adria [2 ,5 ]
Torrens, Marta [3 ,4 ,6 ,7 ]
Paolo Busardo, Francesco [8 ]
Farre, Magi [1 ,2 ,3 ,4 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Clin Pharmacol Dept, Badalona 08916, Spain
[2] Inst Recerca Germans Trias HUGTiP IGTP, Badalona 08916, Spain
[3] Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Cerdanyola Del Valles 08193, Spain
[4] Univ Autonoma Barcelona, Dept Psychiat, Cerdanyola Del Valles 08193, Spain
[5] Hosp Badalona Germans Trias & Pujol, Pharm Dept, Badalona 08916, Spain
[6] Parc Salut Mar, Drug Addict Program, Inst Neuropsiquiatria, Barcelona 08003, Spain
[7] Inst Hosp del Mar Recerca Med PSMAR IMIM, Barcelona 08003, Spain
[8] Univ Politecn Marche, Dept Excellence Biomed Sci & Publ Hlth, I-60121 Ancona, Italy
来源
MEDICINA-LITHUANIA | 2020年 / 56卷 / 06期
关键词
oral cannabis; oral THC; medical use; cannabis edibles; pharmacokinetics; DELTA(9)-TETRAHYDROCANNABINOL THC; HEALTHY-VOLUNTEERS; MEDICINAL CANNABIS; PHARMACOKINETICS; PLASMA; BLOOD; DRONABINOL; MARIJUANA; PROFILE; SINGLE;
D O I
10.3390/medicina56060309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: Changes in cannabis legalization regimes in several countries have influenced the diversification of cannabis use. There is an ever-increasing number of cannabis forms available, which are gaining popularity for both recreational and therapeutic use. From a therapeutic perspective, oral cannabis containing Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is a promising route of administration but there is still little information about its pharmacokinetics (PK) effects in humans. The purpose of this systematic review is to provide a general overview of the available PK data on cannabis and THC after oral administration.Materials and Methods: A search of the published literature was conducted using the PubMed database to collect available articles describing the PK data of THC after oral administration in humans.Results: The literature search yielded 363 results, 26 of which met our inclusion criteria. The PK of oral THC has been studied using capsules (including oil content), tablets, baked goods (brownies and cookies), and oil and tea (decoctions). Capsules and tablets, which mainly correspond to pharmaceutical forms, were found to be the oral formulations most commonly studied. Overall, the results reflect the high variability in the THC absorption of oral formulations, with delayed peak plasma concentrations compared to other routes of administration.Conclusions: Oral THC has a highly variable PK profile that differs between formulations, with seemingly higher variability in baked goods and oil forms. Overall, there is limited information available in this field. Therefore, further investigations are required to unravel the unpredictability of oral THC administration to increase the effectiveness and safety of oral formulations in medicinal use.
引用
收藏
页码:1 / 28
页数:21
相关论文
共 61 条
[31]   Neurological Aspects of Medical Use of Cannabidiol [J].
Mannucci, Carmen ;
Navarra, Michele ;
Calapai, Fabrizio ;
Spagnolo, Elvira V. ;
Busardo, Francesco P. ;
Cas, Roberto D. ;
Ippolito, Francesca M. ;
Calapai, Gioacchino .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (05) :541-553
[32]   Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers [J].
Martin-Santos, R. ;
Crippa, J. A. ;
Batalla, A. ;
Bhattacharyya, S. ;
Atakan, Z. ;
Borgwardt, S. ;
Allen, P. ;
Seal, M. ;
Langohr, K. ;
Farre, M. ;
Zuardi, A. W. ;
McGuire, P. K. .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (32) :4966-4979
[33]   Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg Dronabinol or of a cannabis decoction made with 20 or 60 mg Δ9-THC [J].
Ménétrey, A ;
Augsburger, M ;
Favrat, B ;
Pin, MA ;
Rothuizen, LE ;
Appenzeller, M ;
Buclin, T ;
Mangin, P ;
Giroud, C .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2005, 29 (05) :327-338
[34]   A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans [J].
Millar, Sophie A. ;
Stone, Nicole L. ;
Yates, Andrew S. ;
O'Sullivan, Saoirse E. .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[35]  
Ministero della Salute, PROD NAZ SOST ATT OR
[36]  
Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1371/journal.pmed.1000097, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535]
[37]   Acute Illness Associated With Cannabis Use, by Route of Exposure An Observational Study [J].
Monte, Andrew A. ;
Shelton, Shelby K. ;
Mills, Eleanor ;
Saben, Jessica ;
Hopkinson, Andrew ;
Sonn, Brandon ;
Devivo, Michael ;
Chang, Tae ;
Fox, Jacob ;
Brevik, Cody ;
Williamson, Kayla ;
Abbott, Diana .
ANNALS OF INTERNAL MEDICINE, 2019, 170 (08) :531-+
[38]  
Morales P, 2017, PROG CHEM ORG NAT PR, V103, P103, DOI 10.1007/978-3-319-45541-9_4
[39]   Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function [J].
Morgan, Celia J. A. ;
Freeman, Tom P. ;
Hindocha, Chandni ;
Schafer, Grainne ;
Gardner, Chelsea ;
Curran, H. Valerie .
TRANSLATIONAL PSYCHIATRY, 2018, 8
[40]  
Mueller JK, 2016, NEUROPSYCHOPHARMACOL, V41, pS589